n.a. (ACT)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Shares Outstanding 392.44M
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Jim Cramer: There’s No Way We’ll See More Railroad M&A

Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Federal Reserve to Reassess Global Risks in Minutes on Wednesday

Investors are gearing up for another assessment of the global economy, as the Fed Prepares to release the minutes of its March meeting.

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?

Can Allergan-Pfizer Survive Treasury's New Crackdown on Inversions?

The latest rules are seen likely to prompt a rethink of the $150 billion pharmaceuticals deal.

Jim Cramer: The Allergan-Pfizer Deal Is Absolutely Dead

Jim Cramer: The Allergan-Pfizer Deal Is Absolutely Dead

Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.

Jim Cramer: Valeant Needs a Government Monitor

Jim Cramer: Valeant Needs a Government Monitor

TheStreet's Jim Cramer said Valeant Pharmaceuticals' (VRX) move to appoint billionaire investor Bill Ackman to the board of directors isn't enough and a government monitor is needed.

Healthcare M&A Resilient Despite Economic Woes

Healthcare M&A Resilient Despite Economic Woes

Despite the financial hardships plaguing some economies, healthcare M&A is still on the rise and experts indicate there is no sign of it slowing.

Valeant Pharmaceuticals Buys Maker of Female Viagra, Sprout for $1B

Valeant Pharmaceuticals Buys Maker of Female Viagra, Sprout for $1B

Laval, Quebec-based Valeant Pharmaceuticals International Inc. (VRX) announced on Thursday that it would purchase privately owned Sprout Pharmaceuticals Inc. for $1 billion.

Today's Stocks Driving Success For The Drugs Industry

Today's Stocks Driving Success For The Drugs Industry

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Weekly Roundup

We put our large cash position to work this week, building our stakes in two portfolio names.

Jim Cramer -- Let's Face It, Allergan's Kythera Acquisition Is 'Brilliant'

Jim Cramer -- Let's Face It, Allergan's Kythera Acquisition Is 'Brilliant'

The Botox maker now has complete 'facial domination,' Cramer says.

5 Stocks Larry Robbins Loves Even Though They're Not Health Care Stocks

5 Stocks Larry Robbins Loves Even Though They're Not Health Care Stocks

Glenview Capital's Larry Robbins has hit the nail on the head with his health care picks in recent years, but they're not his only investments you should be watching.

Failed Greece Negotiations Hit Futures; Dollar Worries Persist

Failed Greece Negotiations Hit Futures; Dollar Worries Persist

But investors are likely to be wary ahead of the Fed meeting.

Weekly Roundup

This week, we added to two portfolio holdings, took some profits off the table in others, and exited one position.

Jim Cramer's Top Takeaways: Actavis, Rite Aid, Receptos

Jim Cramer's Top Takeaways: Actavis, Rite Aid, Receptos

Cramer is impressed by Rite Aid, even though it is expensive, and Receptos, which he says is the best early-stage biotech.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching earnings from Sears, Lululemon and Cisco, among others, next week.

Weekly Roundup

We made few moves in the portfolio this week as mixed data produced volatile trading across asset classes.

Why Actavis Shares Are Underperforming

We have tremendous confidence in Actavis' ability to deliver.

Weekly Roundup

This week, we swapped new positions for old in the energy and health care sectors, as the market ended in the red.

Actavis Added to Citigroup's U.S. Focus List

Actavis' attractive near to medium-term organic growth profile is not reflected in current valuation levels.

3 Drugs Stocks Nudging The Industry Higher

3 Drugs Stocks Nudging The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

FDA Approval of Viberzi Is Bullish for Actavis

The new drug complements the company's offer in the field.

Weekly Roundup

We added two new positions to the portfolio this week as the S&P 500 moved slightly higher.

5 Investments That Show John Paulson Knows How to Play M&A

5 Investments That Show John Paulson Knows How to Play M&A

John Paulson said in a 2014 interview that he expected high levels of M&A activity to continue "for the foreseeable future." He has invested accordingly, and it is paying off.

Jim Cramer Says Own Ebay as a Way to Play Its Split with Paypal

Jim Cramer Says Own Ebay as a Way to Play Its Split with Paypal

TheStreet’s Jim Cramer answers your Twitter questions from the floor of the New York Stock Exchange.

5 Stocks the Biggest Hedge Funds Bought Last Quarter

5 Stocks the Biggest Hedge Funds Bought Last Quarter

Hedge funds socked money into health care, industrials and energy last quarter, according to S&P Capital IQ. Here are the top five stock purchases made by large hedge fund managers.

This Is Why I Don't Like the Airlines

Today shows why they're a problem, as are all transports.

Hedge Funds Love These 5 Big Stocks -- but Should You?

Hedge Funds Love These 5 Big Stocks -- but Should You?

Hedge funds were buying these five stocks in bulk in the most recently reported quarter, but that doesn't necessarily mean you should add them to your portfolio too.

Dan Loeb Sold Out of Alibaba -- Here’s Where He’s Investing Instead

Dan Loeb Sold Out of Alibaba -- Here’s Where He’s Investing Instead

Three years after first making the case for Alibaba, Dan Loeb is done. He has set his sights on other investments, instead.